Our results demonstrated for the first time that the preferential receptor utilization of cancer cells during co-treatment with TRAIL and anti-neoplastic agents could be changed as regulation of receptors expression can differ from that induced by the same agents separately. Here, TNFSF10 is linked to cancer.